Labaran Omicron na Gaggawa: Johnson & Johnson na iya yin Pfizer da Moderna mafi inganci

Adadin ƙasashen da sabon nau'in Omicron ya buge
Adadin ƙasashen da sabon nau'in Omicron ya buge
Avatar na Juergen T Steinmetz

The Johnson & Johnson COVID-19 Booster, An Gudanarwa Watanni Shida Bayan Tsarin Kashi Biyu na BNT162b2, Yana Nuna Babban Haɓakawa a Amsoshin Antibody da T-cell.

 Johnson & Johnson (NYSE: JNJ) (Kamfanin) a yau sun sanar da sakamako na farko daga wani bincike mai zaman kansa, ciki har da wani yanki na mahalarta daga binciken Janssen-sponsored COV2008, wanda Dan Barouch, MD, Ph.D., et al. na Cibiyar Kiwon Lafiya ta Beth Israel Deaconess (BIDMC), wacce ta nuna cewa wani karin harbin rigakafin Johnson & Johnson COVID-19 (Ad26.COV2.S), wanda aka gudanar a cikin watanni shida bayan tsarin farko na kashi biyu na BNT162b2, ya karu duka biyun antibody. da kuma martanin T-cell. Waɗannan sakamakon suna nuna yuwuwar fa'idodin haɓakar haɓakar haɓaka (mix-da-match). An buga labarin da ke kwatanta waɗannan sakamakon wannasura.

"Akwai shaidun farko da ke ba da shawarar cewa hanyar haɓakawa-da-match na iya ba wa daidaikun mutane da martani daban-daban game da COVID-19 fiye da tsarin haɓaka ɗabi'a," in ji Dan Barouch, MD, Ph.D., Daraktan Cibiyar. Binciken Virology da Nazarin Alurar rigakafi a BIDMC. "A cikin wannan binciken na farko, lokacin da aka ba da adadin ƙarar Ad26.COV2.S ga mutane watanni shida bayan tsarin farko tare da rigakafin BNT162b2, an sami kwatankwacin karuwar martanin rigakafin rigakafi a cikin mako huɗu bayan haɓakawa da haɓakar haɓaka. Amsoshin CD8+ T-cell tare da Ad26.COV2.S idan aka kwatanta da BNT162b2."

Mathai Mammen, MD, Ph.D., Shugaban Duniya, Janssen ya ce "Wadannan sakamakon suna ba da fa'idodin kimiyya masu mahimmanci don rigakafinmu idan aka yi amfani da su azaman haɓaka-da-match kuma suna iya taimakawa wajen sanar da dabarun haɓakawa tare da manufar dakile cutar," in ji Matthai Mammen, MD, Ph.D., Shugaban Duniya, Janssen. Bincike & Ci gaba, Johnson & Johnson. "Wadannan bayanan sun kara da tarin shaidun da ke nuna cewa hade-da-daidaita kashi na rigakafin Johnson & Johnson COVID-19 sun sami nasarar haɓaka martanin ban dariya da martanin wayar hannu game da asalin nau'in SARS-CoV-2, haka kuma bambance-bambancen Beta da Delta."

An ƙarfafa bayanan hese Phase 2 ta sakamakon farko daga binciken asibiti na UK COV-BOOST da aka buga a The Lancet, wanda ya nuna cewa biyo bayan allurar farko tare da allurai biyu na ko dai BNT162b2 (n=106) ko ChAdOx1 nCov-19 (n=108), karin adadin maganin rigakafin Johnson & Johnson COVID-19 ya karu da martanin antibody da T-cell.

Martanin salula (T-Cell).

n wannan binciken na farko, haɓakawa tare da rigakafin Johnson & Johnson COVID-19 bayan tsarin rigakafin farko na BNT162b2 ya bayyana yana haifar da haɓaka mafi girma a cikin martanin CD8+ T-cell fiye da haɓakawa tare da BNT162b2. Waɗannan bayanan amsawar T-cell suna ba da bambance-bambance tsakanin martanin rigakafi bayan haɓaka haɓakawa tare da BNT162b2, da haɓaka-da-match tare da rigakafin Johnson & Johnson COVID-19 biyo bayan tsarin farko na BNT162b2.

Alurar rigakafin Johnson & Johnson COVID-19 yana ba da damar Janssen's AdVac® fasaha da rigakafi mai shiga tsakani, gami da CD4+ da CD8+ martani. Kwayoyin T-suna iya kaiwa hari da lalata ƙwayoyin da kwayar cutar ta kamu da cutar da ke haifar da COVID-19. Musamman, CD8+ T-cell suna iya lalata ƙwayoyin cuta kai tsaye kuma CD4+ T-cell suna taimakon su.

Martanin Humoral (Antibody). 

Dukansu rigakafin Johnson & Johnson COVID-19 da BNT162b2 a matsayin masu haɓakawa sun haifar da irin wannan neutralizing da ɗaure matakan rigakafin cutar kan asalin SARS-CoV-2, da kuma bambance-bambancen Delta da Beta, makonni huɗu bayan haɓakar. Koyaya, bayan juzu'in haɓaka-da-match na rigakafin Johnson & Johnson COVID-19, ƙwayoyin rigakafi sun ci gaba da ƙaruwa na aƙalla makonni huɗu yayin da a cikin mutanen da suka sami haɓaka mai kama da allurar BNT162b2, ƙwayoyin rigakafi sun ƙi daga mako biyu zuwa mako. hudu bayan haɓakawa.

Tsakanin ƙwayoyin cuta na iya ɗaure ƙwayoyin cuta ta hanyar da za ta toshe kamuwa da cuta kuma ta keɓance kwayar cutar zuwa sashin numfashi na sama. Daure ƙwayoyin rigakafi na iya ɗaure su da furotin mai karu da ƙwayoyin cuta kuma su hana ƙwayar cutar ta hanyar ayyukan antiviral marasa tsaka-tsaki.

Nazarin Zane

Don wannan binciken, wani samfurin biorepository a Beth Israel Deaconess Medical Center (BIDMC) ya sami samfurori daga mutanen da suka karɓi maganin BNT162b2. Mahalarta ko dai sun ci gaba da bibiya a cikin biorepository kuma an haɓaka su tare da 30 ug BNT162b2 (n = 24) ko kuma sun shiga cikin binciken COV2008 (NCT04999111) kuma an haɓaka su tare da 5, 2.5, ko 1 × 1010 vp na rigakafin Johnson & Johnson COVID-19 (n=41). Binciken COV2008 shine Johnson & Johnson wanda aka dauki nauyin, mai gudana, gwajin asibiti na Mataki na 2 (VAC31518COV2008) don kimanta maganin COVID-19 a matsayin mai haɓakawa a cikin manya masu shekaru 18 da haihuwa.

Kwamitin Ba da Shawarar Cibiyoyin Kula da Cututtuka na Amurka (CDC) kan Ayyukan rigakafi (ACIP) ya ba da shawarar rigakafin Johnson & Johnson COVID-19 a matsayin mai haɓaka ga duk waɗanda suka cancanta masu shekaru 18 da haihuwa waɗanda suka sami izini na rigakafin COVID-19.

Johnson & Johnson na ci gaba da gabatar da bayanan da suka dace ga sauran masu mulki, Hukumar Lafiya ta Duniya (WHO) da Kungiyoyin Ba da Shawarwari na Fasaha ta Kasa (NITAGs) a duk duniya don sanar da yanke shawara kan dabarun sarrafa rigakafin na gida, kamar yadda ake bukata.

Tare da haɗin gwiwar ƙungiyoyin ilimi a Afirka ta Kudu da ma duniya baki ɗaya, Kamfanin yana kimanta tasirin rigakafin COVID-19 a cikin bambance-bambancen, yanzu gami da sabbin kuma yana yaduwa cikin sauri. Omicron bambancin. Bugu da kari, Kamfanin yana bin takamaiman rigakafin Omicron kuma zai ci gaba da shi yadda ake buƙata.

Don ƙarin bayani kan hanyoyin da Kamfanin ke bi don taimakawa yaƙi da cutar, ziyarci: www.jnj.com/covid-19.

Amfani da Izini

Alurar rigakafin Johnson & Johnson COVID-19, wanda kuma ake kira da Janssen COVID-19 Vaccine, an ba da izini don amfani a ƙarƙashin Izinin Amfani da Gaggawa (EUA) don yin rigakafi mai aiki don hana Cutar Coronavirus 2019 (COVID-19) wanda ke haifar da matsanancin matsanancin numfashi. cutar coronavirus 2 (SARS-CoV-2).

  • Tsarin rigakafi na farko na Janssen COVID-19 Alurar rigakafi kashi ɗaya ne (0.5 ml) ana gudanarwa ga mutane masu shekaru 18 da haihuwa. 
  • Janssen COVID-19 guda ɗaya na ƙarar maganin rigakafi (0.5 ml) ana iya ba da shi aƙalla watanni 2 bayan rigakafin farko ga mutane masu shekaru 18 da haihuwa. 
  • Za'a iya ba da kashi ɗaya na rigakafin Janssen COVID-19 (0.5 ml) ga mutane masu shekaru 18 da haihuwa a matsayin adadin haɓakar haɓakawa daban-daban bayan kammala rigakafin farko tare da wani izini ko yarda da rigakafin COVID-19. Matsakaicin adadin alluran ƙararrawa na heterologous daidai yake da wanda aka ba da izini don ƙara adadin maganin da aka yi amfani da shi don rigakafin farko.

MUHIMMAN BAYANI AKAN KIYAYYA

ko da mai ba da rigakafin game da duk yanayin lafiyar ku, gami da idan kun:

  • suna da wani rashin lafiyan 
  • yi zazzabi 
  • suna da matsalar zubar jini ko kuma suna kan sikarin jini 
  • suna da rigakafi ko kuma suna kan maganin da ke shafar tsarin garkuwar jikin ku 
  • suna da ciki ko shirin yin ciki 
  • suna shayarwa 
  • sun sami wani allurar COVID-19 
  • sun taɓa yin suma cikin haɗin gwiwa da allura

Bai kamata ku sami Janssen COVID-19 Vaccine ba idan kun:

  • yana da mummunan rashin lafiyan bayan allurar baya ta wannan allurar 
  • ya kamu da rashin lafiya mai tsanani ga kowane sashi na wannan maganin.

Za a ba ku Allurar Janssen COVID-19 a matsayin allura a cikin tsoka.

Alurar riga kafi: Ana yin rigakafin Janssen COVID-19 azaman kashi ɗaya.

Adadin Ƙarfafawa:

  • Za'a iya ba da kashi ɗaya mai ƙarfafawa na rigakafin Janssen COVID-19 aƙalla watanni biyu bayan rigakafin farko tare da Janssen COVID-19 Vaccine. 
  • Za'a iya ba da kashi ɗaya na rigakafin Janssen COVID-19 ga mutane masu shekaru 18 da haihuwa waɗanda suka kammala rigakafin farko tare da wani izini daban ko yarda da rigakafin COVID-19. Da fatan za a bincika tare da mai ba da lafiyar ku game da lokacin adadin ƙarar ƙara.

Illolin da aka ruwaito tare da Janssen COVID-19 Vaccine sun haɗa da:

  • Halin wurin allura: zafi, jajayen fata, da kumburi. 
  • Babban illa: ciwon kai, jin gajiya sosai, ciwon tsoka, tashin zuciya, zazzabi. 
  • Kumbura Lymph. 
  • Jinin jini. 
  • Jin da ba a saba gani ba a cikin fata (kamar tingling ko jin rarrafe) (paresthesia), raguwar ji ko ji, musamman a cikin fata (hypoesthesia). 
  • Ringing mai dawwama a cikin kunnuwa (tinnitus). 
  • Zawo, amai.

Akwai dama mai nisa cewa rigakafin Janssen COVID-19 na iya haifar da mummunan rashin lafiyan. Muguwar rashin lafiyan yakan faru a cikin 'yan mintoci kaɗan zuwa awa ɗaya bayan samun allurar Janssen COVID-19. Don haka, mai ba da rigakafin ku na iya tambayar ku da ku zauna a wurin da kuka karɓi maganin ku don saka idanu bayan rigakafin. Alamomin rashin lafiyar mai tsanani na iya haɗawa da:

  • Dama mai wuya 
  • Kumburin fuska da makogwaro 
  • Bugun zuciya 
  • Mugun kururuwa a jikinka 
  • Dizziness da rauni

Jini na jini tare da ƙananan matakan platelets

Ruwan jini da ya shafi tasoshin jini a cikin kwakwalwa, huhu, ciki, da ƙafafu tare da ƙananan matakan platelet (ƙwayoyin jinin da ke taimaka wa jikin ku daina zubar jini), sun faru a wasu mutanen da suka karɓi Allurar Janssen COVID-19. A cikin mutanen da suka haɓaka waɗannan ɗigon jini da ƙananan matakan platelet, alamun sun fara kusan mako ɗaya zuwa biyu bayan alurar riga kafi. Bayar da rahoton waɗannan dunƙulewar jini da ƙananan matakan platelet ya kasance mafi girma a cikin mata masu shekaru 18 zuwa 49. Damar samun wannan ta faru tana da nisa. Ya kamata ku nemi kulawar likita nan da nan idan kuna da ɗayan alamun da ke biye bayan samun Janssen COVID-19 Vaccine:

  • Karancin numfashi, 
  • Ciwon kirji, 
  • kumburin kafa, 
  • Ciwon ciki na dawwama, 
  • Ciwon kai mai tsanani ko na ci gaba ko duhun gani, 
  • Sauƙaƙen kururuwa ko ƙananan tabo na jini a ƙarƙashin fata fiye da wurin allurar.

Waɗannan ƙila ba su zama duk illolin da ke tattare da rigakafin Janssen COVID-19 ba. Mummunan sakamako da ba zato ba tsammani na iya faruwa. Har yanzu ana nazarin rigakafin Janssen COVID-19 a gwajin asibiti.

Guillain Barré ciwo

Ciwon Guillain Barré (cuta ce ta jijiyoyin jiki wanda tsarin garkuwar jiki ke lalata ƙwayoyin jijiya, yana haifar da raunin tsoka kuma wani lokacin naƙasa) ya faru a wasu mutanen da suka karɓi Allurar Janssen COVID-19. A yawancin waɗannan mutanen, alamun sun fara a cikin kwanaki 42 bayan karɓar Janssen COVID-19 Vaccine. Damar samun wannan faruwar ta ragu sosai. Yakamata ku nemi kulawar likita nan da nan idan kun sami ɗayan alamun da ke biyo bayan karɓar Janssen COVID-19 Vaccine:

  • Rauni ko raɗaɗi, musamman a ƙafafu ko hannaye, wanda ke daɗa muni da yaduwa zuwa wasu sassan jiki. 
  • Wahalar tafiya. 
  • Wahalar motsin fuska, gami da magana, tauna, ko hadiyewa. 
  • Hanyoyi biyu ko rashin iya motsa idanu. 
  • Wahala tare da sarrafa mafitsara ko aikin hanji.

Game da marubucin

Avatar na Juergen T Steinmetz

Juergen T Steinmetz

Juergen Thomas Steinmetz ya ci gaba da aiki a masana'antar tafiye-tafiye da yawon buɗe ido tun yana saurayi a Jamus (1977).
Ya kafa eTurboNews a cikin 1999 azaman wasiƙar farko ta yanar gizo don masana'antar yawon shakatawa ta duniya.

Labarai
Sanarwa na
bako
1 Comment
sabon
tsofaffin
Bayanin Cikin Lissafi
Duba duk maganganu
1
0
Za a son tunanin ku, don Allah sharhi.x
()
x
Share zuwa...